Pharmaceutical Industry Today

Renal Insufficiency Market Size, Share, Industry, Forecast and Outlook (2024-2031)

A condition known as renal insufficiency, often referred to as kidney insufficiency or kidney failure, occurs when the kidneys are unable to efficiently carry out their essential tasks, which reduces their capacity to filter waste materials and extra fluids from the circulation.
Published 26 February 2024

Renal Insufficiency Market

Global Renal Insufficiency Market Poised for High Growth Rates by 2031

The Global Renal Insufficiency Market is anticipated to witness significant growth with a high Compound Annual Growth Rate (CAGR) during the forecast period spanning from 2024 to 2031.

Renal insufficiency, commonly known as kidney insufficiency or kidney failure, denotes a condition where the kidneys fail to efficiently carry out essential functions, leading to an accumulation of waste materials, electrolyte imbalances, and fluid retention in the body. This market is driven by factors such as the rising prevalence of chronic diseases, aging demographics, advancements in medical technologies, and increased awareness.

Market expansion is further propelled by innovations in renal insufficiency diagnoses, therapies, and treatments, including advancements in dialysis techniques and the introduction of new drugs, all of which have contributed to improved patient outcomes.

Market Summary: Metrics and Insights

CAGR: High

Years Covered: 2024-2031

Segments Covered: Treatment Type, Disease Stage, Sales Channel, and Region

Regions Covered: North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Fastest Growing Region: Asia-Pacific

Largest Region: North America

To know more Insights Download Sample :

Renal Insufficiency Market Dynamics

The market landscape is characterized by significant collaborations, technological advancements, and research activities aimed at addressing unmet medical needs in renal care. Major players such as Chinook Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Charles River Laboratories International, Inc., and Roche are actively involved in pioneering treatments and therapies for renal diseases.

Recent collaborations include a partnership between Chinook Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. for the development of an antisense oligonucleotide (ASO) medication targeting severe chronic kidney diseases. Similarly, Charles River Laboratories International, Inc. has entered into a collaboration with Purespring Therapeutics to advance gene therapy solutions for kidney illnesses.

Roche's licensing agreement with Ionis Pharmaceuticals for the development of a rare kidney disease treatment candidate further underscores the collaborative efforts within the industry to address unmet medical needs in renal care.

Technological Advancements and Challenges

Advancements in nephrology, including improved renal function estimation techniques and novel therapeutic strategies such as wearable prosthetic kidneys and stem cell-derived therapies, offer promise for the future of renal care. However, challenges such as high treatment costs and the complexities of drug development persist, necessitating concerted efforts from stakeholders to overcome these hurdles.

Market Segment Analysis and Geographical Share

The market is segmented based on treatment type, disease stage, sales channel, and region. Chronic Kidney Disease (CKD) Stages represent a significant portion of the market share, highlighting the importance of addressing various stages of renal insufficiency in therapeutic interventions.

North America remains a dominant force in the global renal insufficiency market, with significant developments such as the acceptance of Jardiance (empagliflozin) tablets by the U.S. Food and Drug Administration for the treatment of chronic kidney disease.

Impact of COVID-19 and Geopolitical Events

The COVID-19 pandemic has posed unprecedented challenges for the healthcare industry, including disruptions in healthcare services and challenges in managing renal insufficiency amidst the pandemic. Additionally, geopolitical events such as the Russia-Ukraine conflict have the potential to impact healthcare infrastructure and access to renal care services in affected regions.

Key Developments and Companies

Key developments include initiatives such as the partnership between and Boehringer Ingelheim Pharmaceuticals, Inc. to support at-home testing and educational efforts for patients at risk of chronic kidney disease.

Major global players in the renal insufficiency market include, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Roche, Charles River Laboratories International, Inc., Purespring Therapeutics, Chinook Therapeutics, Inc., AstraZeneca, Baxter, and Nipro Corp.

Related Reports:

nonalcoholic fatty liver disease market 

warm autoimmune hemolytic anemia market

cutaneous lupus erythematosus market             

gm1 gangliosidosis treatment market

cloves syndrome market

mrna vaccine and therapeutics market

About Us -

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Company Name: DataM Intelligence


Phone: +1 877 441 4866


Other Industry News

Ready to start publishing

Sign Up today!